본문 바로가기

EU · EudraLex Vol.4

EU GMP Part I, Chapter 8

Complaints, Quality Defects and Product Recalls

Status of the document: Revision

조항 목차

  1. PrinciplePrinciple
  2. 8.1Appropriately trained and experienced personnel should be responsible for managing complaint and quality defect investigations and for deci…
  3. 8.2Sufficient trained personnel and resources should be made available for the handling, assessment, investigation and review of complaints an…
  4. 8.3The use of inter-disciplinary teams should be considered, including appropriately trained Quality Management personnel.
  5. 8.4In situations in which complaint and quality defect handling is managed centrally within an organisation, the relative roles and responsibi…
  6. 8.5There should be written procedures describing the actions to be taken upon receipt of a complaint. All complaints should be documented and…
  7. 8.6Special attention should be given to establishing whether a complaint or suspected quality defect relates to falsification.
  8. 8.7As not all complaints received by a company may represent actual quality defects, complaints which do not indicate a potential quality defe…
  9. 8.8There should be procedures in place to facilitate a request to investigate the quality of a batch of a medicinal product in order to suppor…
  10. 8.9When a quality defect investigation is initiated, procedures should be in place to address at least the following: i. The description of th…
  11. 8.10The information reported in relation to possible quality defects should be recorded, including all the original details. The validity and e…
  12. 8.11If a quality defect is discovered or suspected in a batch, consideration should be given to checking other batches and in some cases other…
  13. 8.12Quality defect investigations should include a review of previous quality defect reports or any other relevant information for any indicati…
  14. 8.13The decisions that are made during and following quality defect investigations should reflect the level of risk that is presented by the qu…
  15. 8.14As comprehensive information on the nature and extent of the quality defect may not always be available at the early stages of an investiga…
  16. 8.15Quality defects should be reported in a timely manner by the manufacturer to the marketing authorisation holder/sponsor and all concerned C…
  17. 8.16An appropriate level of root cause analysis work should be applied during the investigation of quality defects. In cases where the true roo…
  18. 8.17Where human error is suspected or identified as the cause of a quality defect, this should be formally justified and care should be exercis…
  19. 8.18Appropriate CAPAs should be identified and taken in response to a quality defect. The effectiveness of such actions should be monitored and…
  20. 8.19Quality defect records should be reviewed and trend analyses should be performed regularly for any indication of specific or recurring prob…
  21. 8.20There should be established written procedures, regularly reviewed and updated when necessary, in order to undertake any recall activity or…
  22. 8.21After a product has been placed on the market, any retrieval of it from the distribution network as a result of a quality defect should be…
  23. 8.22Recall operations should be capable of being initiated promptly and at any time. In certain cases recall operations may need to be initiate…
  24. 8.23The batch/product distribution records should be readily available to the persons responsible for recalls, and should contain sufficient in…
  25. 8.24In the case of investigational medicinal products, all trial sites should be identified and the countries of destination should be indicate…
  26. 8.25Consideration should be given following consultation with the concerned Competent Authorities, as to how far into the distribution network…
  27. 8.26All concerned Competent Authorities should be informed in advance in cases where products are intended to be recalled. For very serious iss…
  28. 8.27It should also be considered whether the proposed recall action may affect different markets in different ways, and if this is the case, ap…
  29. 8.28Recalled products should be identified and stored separately in a secure area while awaiting a decision on their fate. A formal disposition…
  30. 8.29The progress of the recall process should be recorded until closure and a final report issued, including a reconciliation between the deliv…
  31. 8.30The effectiveness of the arrangements in place for recalls should be periodically evaluated to confirm that they remain robust and fit for…
  32. 8.31In addition to recalls, there are other potential risk-reducing actions that may be considered in order to manage the risks presented by qu…
표지·목차 원문

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Health systems and products Medicinal products – quality, safety and efficacy

Brussels, 13 August 2014 Ares(2014)2674297

EudraLex

The Rules Governing Medicinal Products in the European Union

Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

Part 1 Chapter 8: Complaints, Quality Defects and Product Recalls

Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.

Status of the document: Revision

Reasons for changes: Extensive changes have been made to this Chapter which now reflect that Quality Risk Management principles should be applied when investigating quality defects or complaints and when making decisions in relation to product recalls or other risk-mitigating actions. It emphasises the need for the cause(s) of quality defects or complaints to be investigated and determined, and that appropriate preventative actions are put in place to guard against a recurrence of the issue and clarifies expectations and responsibilities in relation to the reporting of quality defects to the Competent Authorities.

Deadline for coming into operation: 1 March 2015.

1

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.